NSE · QUESTLAB
Quest Laboratories Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹108 Cr with net profit ₹14 Cr — a 12.54% net margin, versus 12.19% the period before.
Shareholding
As of 2026-03-31
- Promoter66.78%
- Public30.56%
- FII0.61%
- DII2.04%
911 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.82× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #28 of 50 by market cap · medians across 42 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,85,319 Cr | 84.56 | 22.04 | 25.49% | 15.55% |
| Ajanta Pharma Limited | ₹42,933 Cr | 160.96 | 9.52 | 23.33% | 19.37% |
| Gland Pharma Limited | ₹41,520 Cr | 113.07 | 4 | 9.92% | 15.98% |
| Rubicon Research Limited | ₹24,811 Cr | 100.55 | 19.25 | 19.14% | 14.07% |
| Caplin Point Laboratories Ltd. | ₹19,279 Cr | 113.33 | 5.37 | 17.88% | 29.32% |
| Eris Lifesciences Limited | ₹19,056 Cr | 66.76 | 4.88 | 15.87% | 19.89% |
| Shilpa Medicare Ltd. | ₹11,793 Cr | 50.54 | 4.55 | 9.39% | 15.81% |
| Marksans Pharma Limited | ₹11,719 Cr | 28.05 | 3.88 | 13.82% | 14.16% |
| Senores Pharmaceuticals Limited | ₹5,952 Cr | 47.1 | 6.38 | 12.36% | 18.59% |
| Bliss GVS Pharma Ltd. | ₹4,827 Cr | 141.35 | 4.04 | 8.95% | 11.15% |
| Quest Laboratories Ltd.(this company) | ₹156 Cr | 54.6 | 1.61 | 15.51% | 13.43% |
AI analysis
AI-generated · google/gemini-2.5-flashQuest Laboratories Ltd. is listed with a market capitalization of Rs 159 Cr. The company reported revenue of Rs 108.21 Cr and a net profit margin of 13.43%. Its earnings per share (EPS) stands at Rs 9.16, with a return on equity (ROE) of 15.51% and return on capital employed (ROCE) of 26.88%.
Positives
- +The company has a strong Return on Capital Employed (ROCE) of 26.88%.
- +Net profit has shown an upward trend, increasing from Rs 0.655 Cr in Mar 2021 to Rs 13.5664 Cr in Mar 2025.
- +The debt-to-equity ratio of 0.32 is low.
Negatives
- −The FII holding has significantly decreased from 4.5988% in May 2024 to 0.6078% in Mar 2026.
- −Quarterly net profit decreased from Rs 4.03 Cr in Dec 2025 to Rs 2.87 Cr in Mar 2026.
- −The company's profit margin of 13.43% has fluctuated, with annual EPS ranging from Rs 6.07 in Mar 2021 to Rs 8.28 in Mar 2025.
- −The Price-to-Earnings (PE) ratio of 55.8 is higher than the Book Value of Rs 59.08, indicating a higher valuation relative to its book value.
Financial Performance
Quest Laboratories Ltd. reported revenue of Rs 108.2096 Cr for the year ending Mar 2025. This marks a continued increase from Rs 82.7919 Cr in Mar 2024 and Rs 61.8660054 Cr in Mar 2023. Net profit for Mar 2025 was Rs 13.5664 Cr, up from Rs 10.0939 Cr in Mar 2024 and Rs 5.0449027 Cr in Mar 2023.
Profitability & Returns
The company's net profit margin is 13.43%. Return on equity (ROE) is 15.51%, and return on capital employed (ROCE) is 26.88%. Earnings per share (EPS) for the latest period is Rs 9.16, following Rs 8.28 in Mar 2025 and Rs 6.16 in Mar 2024.
Balance Sheet
Quest Laboratories Ltd. has a debt-to-equity ratio of 0.32. The book value per share is Rs 59.08. The company does not currently offer a dividend, with a dividend yield of 0%.
Ownership & Pledges
As of Mar 2026, promoter holding in Quest Laboratories Ltd. is 66.7844%. There are no promoter pledges reported, with promoter pledge at 0%.
Quarterly Performance
In the quarter ending Mar 2026, Quest Laboratories Ltd. reported revenue of Rs 32.4 Cr and a net profit of Rs 2.87 Cr. This compares to revenue of Rs 30.61 Cr and net profit of Rs 4.03 Cr in the preceding quarter (Dec 2025). The EBITDA for Mar 2026 was Rs 2.62 Cr.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: Mar 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.